BioSpace News Archive

BELLUS Health Inc. announced that two abstracts describing the patient medical journey and the negative impact of RCC on quality of life will be presented at the upcoming American Academy of Allergy, Asthma & Immunology Annual Meeting, being held in San Antonio, Texas from February 24-27, 2023.

Toragen, Inc., a San Diego-based biotechnology company focused on developing, repurposing and commercializing uniquely selective drugs targeting cancers caused by the human papillomavirus (“HPV”), announced today that it has promoted Rick Lumpkin, PhD to the role of Chief Scientific Officer.

Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, will report fourth quarter 2022 financial results after the close of trading on Wednesday, March 1.

Align Technology, Inc. announced that after nearly six years with Align, Yuval Shaked, executive vice president and managing director of iTero scanner and services, has decided to leave the company for personal reasons and spend more time with his family.

Verily, an Alphabet company focused on precision health, announced the appointment of Utpal Koppikar as Chief Financial Officer.

MediciNova, Inc. today announced that Health Canada has completed its review of the clinical trial application and has granted authorization to commence a grant-funded, multi-center, randomized, clinical trial to evaluate MN-166 (ibudilast) and other therapies for the treatment of Long COVID, the lingering symptoms of COVID-19.

Fulcrum Therapeutics, Inc.® (Nasdaq: FULC) today announced that management will participate in a virtual presentation at the SVB Securities Global Biopharma Conference on Wednesday, February 15, 2023 at 10:00 AM ET.

Medexus Pharmaceuticals announced its operating and financial results and provided a business update for the company’s third fiscal quarter ended December 31, 2022.

Nimbus Therapeutics, LLC announced the closing of Takeda’s acquisition of Nimbus Lakshmi, Inc., a wholly-owned subsidiary of Nimbus, and its tyrosine kinase 2 inhibitor program, which includes the oral, selective allosteric TYK2 inhibitor NDI-034858, now known as TAK-279.

EnPlusOne Biosciences, Inc. today announced that Jonathan K. Watts, Ph.D., Professor, RNA Therapeutics Institute and Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Chan Medical School, has been appointed to the company’s Scientific Advisory Board.